{"id":"NCT03150719","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in OrkambiÂ® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)","officialTitle":"Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-24","primaryCompletion":"2018-08-09","completion":"2018-08-09","firstPosted":"2017-05-12","resultsPosted":"2019-09-12","lastUpdate":"2019-09-12"},"enrollment":98,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Tezacaftor/Ivacaftor","otherNames":["TEZ/IVA; VX-661/VX-770"]},{"type":"DRUG","name":"Ivacaftor","otherNames":["VX-770; IVA"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"Study VX16-661-114 (Study 114) is a Phase 3b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in subjects aged 12 years and older with CF who are homozygous for the F508del mutation on the cystic fibrosis transmembrane conductance regulator gene (CFTR) gene and who discontinued treatment with Orkambi due to respiratory symptoms considered related to treatment. This study is designed to evaluate the safety and efficacy of Tezacaftor/Ivacaftor (TEZ/IVA).","primaryOutcome":{"measure":"Incidence of Respiratory Adverse Events of Special Interest (RAESIs)","timeFrame":"Day 1 up to Day 84","effectByArm":[{"arm":"Placebo","deltaMin":10,"sd":null},{"arm":"TEZ/IVA","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":13},"locations":{"siteCount":53,"countries":["United States","France","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":47},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Headache","Dyspnoea","Abdominal pain upper"]}}